Metropolis Healthcare Limited — Important, 04-02-2025: Financial Result Updates

**Consolidated Financial Performance Summary**

Metropolis Healthcare Limited has reported a total consolidated income of ₹32,532.30 crore for the quarter ended 31 December 2024, showing a healthy revenue growth of 10.77% compared to ₹29,342.32 crore in the same quarter last year. The increase can be attributed to higher demand for pathology services and expansion in their operational footprint.

Net profit for the quarter stands at ₹4,147.46 crore, reflecting a year-over-year growth of 24.24% from ₹3,685.49 crore. Earnings Per Share (EPS) for the period is reported at ₹6.12, up from ₹5.30, showcasing improved profitability driven by effective cost management and efficiency enhancements in operations.

Total expenses were reported at ₹28,298.74 crore, which marks a growth of 10.24% from ₹25,656.83 crore in the corresponding period last year. Key expense components include an increase in employee benefits expenses and other operational costs, which rose due to expansion initiatives and compensation adjustments, though overall, the company maintains a disciplined approach to cost management.

The balance sheet remains robust, with a healthy equity capital base of ₹1,025.35 crore and other equity of ₹108,591.01 crore, indicating strong financial health. The strategic outlook points towards continued focus on operational efficiency, expansion in service offerings, and maintaining a competitive edge in the healthcare sector.

Given the strong performance, efficient cost control, and promising future prospects, a buy insight is advised for investors looking into Metropolis Healthcare Limited.